Bicuspid Aortic Valve Morphology and Outcomes After Transcatheter Aortic Valve Replacement.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 03 04 2020
revised: 09 06 2020
accepted: 02 07 2020
entrez: 29 8 2020
pubmed: 29 8 2020
medline: 28 1 2021
Statut: ppublish

Résumé

Bicuspid aortic stenosis accounts for almost 50% of patients undergoing surgical aortic valve replacement in the younger patients. Expanding the indication of transcatheter aortic valve replacement (TAVR) toward lower-risk and younger populations will lead to increased use of TAVR for patients with bicuspid aortic valve (BAV) stenosis despite the exclusion of bicuspid anatomy in all pivotal clinical trials. This study sought to evaluate the association of BAV morphology and outcomes of TAVR with the new-generation devices. Patients with BAV confirmed by central core laboratory computed tomography (CT) analysis were included from the international multicenter BAV TAVR registry. BAV morphology including the number of raphe, calcification grade in raphe, and leaflet calcium volume were assessed with CT analysis in a masked fashion. Primary outcomes were all-cause mortality at 1 and 2 years, and secondary outcomes included 30-day major endpoints and procedural complications. A total of 1,034 CT-confirmed BAV patients with a mean age of 74.7 years and Society of Thoracic Surgeons score of 3.7% underwent TAVR with contemporary devices (n = 740 with Sapien 3; n = 188 with Evolut R/Pro; n = 106 with others). All-cause 30-day, 1-year, and 2-year mortality was 2.0%, 6.7%, and 12.5%, respectively. Multivariable analysis identified calcified raphe and excess leaflet calcification (defined as more than median calcium volume) as independent predictors of 2-year all-cause mortality. Both calcified raphe plus excess leaflet calcification were found in 269 patients (26.0%), and they had significantly higher 2-year all-cause mortality than those with 1 or none of these morphological features (25.7% vs. 9.5% vs. 5.9%; log-rank p < 0.001). Patients with both morphological features had higher rates of aortic root injury (p < 0.001), moderate-to-severe paravalvular regurgitation (p = 0.002), and 30-day mortality (p = 0.016). Outcomes of TAVR in bicuspid aortic stenosis depend on valve morphology. Calcified raphe and excess leaflet calcification were associated with increased risk of procedural complications and midterm mortality. (Bicuspid Aortic Valve Stenosis Transcatheter Aortic Valve Replacement Registry; NCT03836521).

Sections du résumé

BACKGROUND
Bicuspid aortic stenosis accounts for almost 50% of patients undergoing surgical aortic valve replacement in the younger patients. Expanding the indication of transcatheter aortic valve replacement (TAVR) toward lower-risk and younger populations will lead to increased use of TAVR for patients with bicuspid aortic valve (BAV) stenosis despite the exclusion of bicuspid anatomy in all pivotal clinical trials.
OBJECTIVES
This study sought to evaluate the association of BAV morphology and outcomes of TAVR with the new-generation devices.
METHODS
Patients with BAV confirmed by central core laboratory computed tomography (CT) analysis were included from the international multicenter BAV TAVR registry. BAV morphology including the number of raphe, calcification grade in raphe, and leaflet calcium volume were assessed with CT analysis in a masked fashion. Primary outcomes were all-cause mortality at 1 and 2 years, and secondary outcomes included 30-day major endpoints and procedural complications.
RESULTS
A total of 1,034 CT-confirmed BAV patients with a mean age of 74.7 years and Society of Thoracic Surgeons score of 3.7% underwent TAVR with contemporary devices (n = 740 with Sapien 3; n = 188 with Evolut R/Pro; n = 106 with others). All-cause 30-day, 1-year, and 2-year mortality was 2.0%, 6.7%, and 12.5%, respectively. Multivariable analysis identified calcified raphe and excess leaflet calcification (defined as more than median calcium volume) as independent predictors of 2-year all-cause mortality. Both calcified raphe plus excess leaflet calcification were found in 269 patients (26.0%), and they had significantly higher 2-year all-cause mortality than those with 1 or none of these morphological features (25.7% vs. 9.5% vs. 5.9%; log-rank p < 0.001). Patients with both morphological features had higher rates of aortic root injury (p < 0.001), moderate-to-severe paravalvular regurgitation (p = 0.002), and 30-day mortality (p = 0.016).
CONCLUSIONS
Outcomes of TAVR in bicuspid aortic stenosis depend on valve morphology. Calcified raphe and excess leaflet calcification were associated with increased risk of procedural complications and midterm mortality. (Bicuspid Aortic Valve Stenosis Transcatheter Aortic Valve Replacement Registry; NCT03836521).

Identifiants

pubmed: 32854836
pii: S0735-1097(20)35934-9
doi: 10.1016/j.jacc.2020.07.005
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03836521']

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1018-1030

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Sung-Han Yoon (SH)

Cedars-Sinai Medical Center, Smidt Cedars-Sinai Heart Institute, Los Angeles, California.

Won-Keun Kim (WK)

Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.

Abhijeet Dhoble (A)

University of Texas Health Science Center, Houston, Texas.

Stephan Milhorini Pio (S)

Leiden University Medical Center, Leiden, the Netherlands.

Vasilis Babaliaros (V)

Emory University School of Medicine, Atlanta, Georgia.

Hasan Jilaihawi (H)

Department of Cardiology and Cardiothoracic Surgery, NYU Langone Medical Center, New York, New York.

Thomas Pilgrim (T)

Bern University Hospital, Bern, Switzerland.

Ole De Backer (O)

Heart Center, Rigshospitalet, Copenhagen, Denmark.

Sabine Bleiziffer (S)

Heart and Diabetes Center North Rhine-Westphalia, Bad Oeynhausen, Germany.

Flavien Vincent (F)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, CHU Lille Institut Cśur Poumon, Cardiology, Inserm U1011, Lille, France.

Tobias Shmidt (T)

Asklepios Klink St. Georg, Hamburg, Germany.

Christian Butter (C)

Heart Center Brandenburg in Bernau & Brandenburg Medical School, Bernau, Germany.

Norihiko Kamioka (N)

Emory University School of Medicine, Atlanta, Georgia.

Lena Eschenbach (L)

German Heart Center Munich, Munich, Germany.

Matthias Renker (M)

Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.

Masahiko Asami (M)

Bern University Hospital, Bern, Switzerland.

Mohamad Lazkani (M)

University of Colorado Health, Loveland, Colorado.

Buntaro Fujita (B)

Ruhr University Bochum, Bad Oeynhausen, Germany; Department of Cardiac and Thoracic Vascular Surgery, University of Schleswig-Holstein, Lübeck Campus, Lübeck, Germany.

Antoinette Birs (A)

University of Washington, Seattle, Washington.

Marco Barbanti (M)

University of Catania, Catania, Italy.

Ashish Pershad (A)

Banner University Medical Center, Phoenix, Arizona.

Uri Landes (U)

Cardiology Department, Rabin Medical Center, Petah Tikva and Tel-Aviv University, Tel-Aviv, Israel.

Brad Oldemeyer (B)

University of Colorado Health, Loveland, Colorado.

Mitusnobu Kitamura (M)

Asklepios Klink St. Georg, Hamburg, Germany.

Luke Oakley (L)

Cedars-Sinai Medical Center, Smidt Cedars-Sinai Heart Institute, Los Angeles, California.

Tomoki Ochiai (T)

Cedars-Sinai Medical Center, Smidt Cedars-Sinai Heart Institute, Los Angeles, California.

Tarun Chakravarty (T)

Cedars-Sinai Medical Center, Smidt Cedars-Sinai Heart Institute, Los Angeles, California.

Mamoo Nakamura (M)

Cedars-Sinai Medical Center, Smidt Cedars-Sinai Heart Institute, Los Angeles, California.

Philip Ruile (P)

Department of Cardiology Angiology II, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany.

Florian Deuschl (F)

Structural Heart Division, University Heart Center, Hamburg, Hamburg, Germany.

Daniel Berman (D)

Cedars-Sinai Medical Center, Smidt Cedars-Sinai Heart Institute, Los Angeles, California.

Thomas Modine (T)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, CHU Lille Institut Cśur Poumon, Cardiology, Inserm U1011, Lille, France; Bordeaux University Hospital, Bordeaux, France.

Stephan Ensminger (S)

Ruhr University Bochum, Bad Oeynhausen, Germany; Department of Cardiac and Thoracic Vascular Surgery, University of Schleswig-Holstein, Lübeck Campus, Lübeck, Germany.

Ran Kornowski (R)

Cardiology Department, Rabin Medical Center, Petah Tikva and Tel-Aviv University, Tel-Aviv, Israel.

Rudiger Lange (R)

German Heart Center Munich, Munich, Germany.

James M McCabe (JM)

University of Washington, Seattle, Washington.

Mathew R Williams (MR)

Department of Cardiology and Cardiothoracic Surgery, NYU Langone Medical Center, New York, New York.

Brian Whisenant (B)

Intermountain Heart Institute, Salt Lake City, Utah.

Victoria Delgado (V)

Leiden University Medical Center, Leiden, the Netherlands.

Stephan Windecker (S)

Bern University Hospital, Bern, Switzerland.

Eric Van Belle (E)

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, CHU Lille Institut Cśur Poumon, Cardiology, Inserm U1011, Lille, France.

Lars Sondergaard (L)

Heart Center, Rigshospitalet, Copenhagen, Denmark.

Bernard Chevalier (B)

Ramsay Generale de Sante Institute Cardiovasculaire Paris-Sud, Massy, France.

Michael Mack (M)

Baylor Scott and White Health Heart Hospital-Plano, Plano, Texas.

Jeroen J Bax (JJ)

Leiden University Medical Center, Leiden, the Netherlands.

Martin B Leon (MB)

Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.

Raj R Makkar (RR)

Cedars-Sinai Medical Center, Smidt Cedars-Sinai Heart Institute, Los Angeles, California. Electronic address: makkarr@cshs.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH